Skip to main content
Premium Trial:

Request an Annual Quote

Sugen Uses Pangea's Tools To Reduce Redundancies


OAKLAND, Calif.--Sugen, a small molecule drug-discovery company wholly owned by Pharmacia and Upjohn, has licensed Pangea Systems' proprietary Clustering and Alignment Tools. Greg Plowman, Sugen's vice-president of molecular biology, said that the performance of Pangea's clustering tool on multiprocessor machines would allow Sugen to reduce the redundancies in its large sequence databases.

Filed under

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.